FDA approves Latuda to treat schizophrenia in adults
The U.S. Food and Drug Administration today approved Latuda (lurasidone HCl) tablets for the treatment of adults with schizophrenia.
Schizophrenia affects about 1 percent of the U.S. population, ages 18 years and older, in a given year. The most prominent symptoms include hallucinations, delusions, disordered thinking and behavior, and suspiciousness. Hearing voices that other people don’t hear is the most common type of hallucination. These experiences can make people with the disorder fearful and withdrawn.
“Schizophrenia can be a devastating illness requiring lifelong treatment,” …

Tardive Dyskinesia/Dystonia, Parkinsonism & Akathisia
SSRI & SSNRI antidepressants induced side-effects (Iatrogenic Extrapyramidal Symptoms) are recognized to be similar to Neuroleptic (anti-psychotic) induced side-effects. These side-effects are known as Tardive Dyskinesia/Dystonia (severe body movement disorder, mostly permanent), Parkinsonism (a sign of future Parkinson’s disease) and Akathisia (a Neurological driven severe mania/agitation that can lead to suicidality, suicide attempts, self-harm & suicide). It is well documented in the medical literature that these neuroleptic induced side-effects refer to damage at dopaminergic neurons in the “motor system” of the
“Basal Ganglia”, a structure deep …